OMDA Omada Health, Inc.
Services-Health Services · Nasdaq · SEC CIK 1611115 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY43.3%
TTM net income YoY153.6%
TTM EPS YoY124.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin70.7%
Operating margin2.1%
Net margin4.2%
FCF margin8.5%
EBITDA margin3.9%
Returns
ROE5.7%
ROA4.4%
ROIC (approx.)28.2%
Asset turnover1.05x
Leverage & solvency
Liabilities / assets21.6%
Debt / equity0.00x
Current ratio4.18x
Interest coverage22.37x
Cash quality & payout
Operating cash flow / net income2.04x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $260.21M | $169.80M | $122.78M |
| Cost of revenue | $89.27M | $66.92M | $52.81M |
| Gross profit | $170.94M | $102.88M | $69.97M |
| R&D expense | $40.68M | $35.92M | $33.74M |
| SG&A expense | $52.18M | $42.55M | $35.98M |
| Operating income | -$11.97M | -$43.65M | -$66.00M |
| Interest expense | $2.53M | $4.51M | $4.71M |
| Pretax income | -$12.78M | -$47.14M | -$67.51M |
| Income tax | $0 | $0 | $0 |
| Net income | -$12.78M | -$47.14M | -$67.51M |
| EBITDA | -$6.48M | -$38.85M | -$61.55M |
| EPS (basic) | -0.35 | -6.11 | -9.52 |
| EPS (diluted) | -0.35 | -6.11 | -9.52 |
| Weighted avg. shares (diluted) | 36.64M | 7.72M | 7.09M |
| Balance sheet | |||
| Cash & equivalents | $222.04M | $76.39M | $115.64M |
| Receivables | $34.59M | $23.42M | — |
| Inventory | $4.49M | $3.30M | — |
| Current assets | $272.93M | $113.06M | — |
| PP&E, net | $7.94M | $5.62M | — |
| Goodwill | $13.24M | $13.24M | — |
| Intangibles | $2.41M | $4.26M | — |
| Total assets | $305.41M | $150.89M | — |
| Current liabilities | $75.73M | $53.95M | — |
| Long-term debt | $0 | $29.77M | — |
| Total debt | $0 | $29.77M | — |
| Total liabilities | $75.73M | $86.26M | — |
| Shareholders' equity | $229.68M | -$384.40M | -$350.11M |
| Net debt | -$222.04M | -$46.62M | — |
| Shares outstanding | 58.43M | 8.16M | — |
| Cash flow statement | |||
| Operating cash flow | $18.25M | -$34.18M | -$49.74M |
| Capital expenditure | $1.32M | $596,000 | $416,000 |
| Free cash flow | $16.93M | -$34.77M | -$50.15M |
| Investing cash flow | -$5.83M | -$3.86M | -$2.92M |
| Financing cash flow | $133.22M | -$1.21M | $179,000 |
| Depreciation & amortization | $5.49M | $4.80M | $4.45M |
| Stock-based compensation | $12.96M | $9.42M | $8.74M |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.